BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Elbakry MMM, ElBakary NM, Hagag SA, Hemida EHA. Pomegranate Peel Extract Sensitizes Hepatocellular Carcinoma Cells to Ionizing Radiation, Induces Apoptosis and Inhibits MAPK, JAK/STAT3, β-Catenin/NOTCH, and SOCS3 Signaling. Integr Cancer Ther 2023;22:15347354221151021. [PMID: 36710483 DOI: 10.1177/15347354221151021] [Reference Citation Analysis]
2 Li W, Wu R, Zhang S, Zhao Y, Li L, Hu Z, Su Q, Mang Y, Zhang X, Dong Y, Zheng K, Ran J, Li L. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma. Clin Transl Oncol 2023. [PMID: 36708372 DOI: 10.1007/s12094-023-03084-x] [Reference Citation Analysis]
3 Qiu X, Xu H, Wang K, Gao F, Xu X, He H. P-21 Activated Kinases in Liver Disorders. Cancers (Basel) 2023;15. [PMID: 36672500 DOI: 10.3390/cancers15020551] [Reference Citation Analysis]
4 Chen J, Sun M, Cui X, Zhang X. Ginsenoside compound K induces mitochondrial apoptosis in human hepatoma cells through Bclaf1-mediated modulation of ERK signaling. Food and Agricultural Immunology 2022;33:799-816. [DOI: 10.1080/09540105.2022.2134313] [Reference Citation Analysis]
5 Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, Wang F, Zhang L, Deng Y. Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. Front Nutr 2022;9:978110. [PMID: 36590214 DOI: 10.3389/fnut.2022.978110] [Reference Citation Analysis]
6 Tu X, Yang J, Zheng Y, Liang C, Tao Q, Tang X, Liu Z, Jiang L, He Z, Xie F, Zheng Y. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study. International Immunopharmacology 2022;113:109401. [DOI: 10.1016/j.intimp.2022.109401] [Reference Citation Analysis]
7 Sung PS, Lee IK, Roh PR, Kang MW, Ahn J, Yoon SK. Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1028728] [Reference Citation Analysis]
8 Laface C, Fedele P, Maselli FM, Ambrogio F, Foti C, Molinari P, Ammendola M, Lioce M, Ranieri G. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers (Basel) 2022;14:4028. [PMID: 36011021 DOI: 10.3390/cancers14164028] [Reference Citation Analysis]
9 Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Diamantis E, Sarantis P, Georgakopoulou VE, Patsouras A, Despotidis M, Prevezanos D, Syllaios A, Marinos G, Koustas E, Vallilas C, Antoniou EA, Kontzoglou K, Savvanis S, Kouraklis G. The Role of SNHG15 in the Pathogenesis of Hepatocellular Carcinoma. JPM 2022;12:753. [DOI: 10.3390/jpm12050753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]